Enlivex Therapeutics (NASDAQ:ENLV) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Enlivex Therapeutics (NASDAQ:ENLV) from a hold rating to a sell rating in a research report released on Saturday morning.

Other analysts have also recently issued reports about the stock. HC Wainwright raised their target price on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 12th. D. Boral Capital reissued a “hold” rating on shares of Enlivex Therapeutics in a research note on Monday, November 24th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $13.00.

Enlivex Therapeutics Stock Up 0.9%

NASDAQ:ENLV opened at $1.11 on Friday. Enlivex Therapeutics has a 52-week low of $0.66 and a 52-week high of $2.10. The firm has a market cap of $263.49 million, a P/E ratio of -2.02 and a beta of 1.62. The business’s 50-day moving average price is $0.95 and its 200 day moving average price is $1.05.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03. Sell-side analysts expect that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Trading of Enlivex Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its position in shares of Enlivex Therapeutics by 244.1% in the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock worth $52,000 after buying an additional 52,553 shares during the period. Susquehanna International Group LLP acquired a new position in Enlivex Therapeutics during the third quarter valued at $57,000. HRT Financial LP lifted its stake in Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after acquiring an additional 135,198 shares in the last quarter. Renaissance Technologies LLC boosted its position in Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after acquiring an additional 156,336 shares during the period. Finally, Citizens Financial Group Inc. RI acquired a new stake in Enlivex Therapeutics during the 3rd quarter worth about $241,000. 1.02% of the stock is owned by institutional investors and hedge funds.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.